Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives

Sabrina Bimonte, Vittorio Albino, Mauro Piccirillo, Aurelio Nasto, Carlo Molino, Raffaele Palaia, Marco Cascella

Research output: Contribution to journalReview articlepeer-review

Abstract

Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the deadliest cancers worldwide. Despite orthotopic liver transplantation and hepatic resection representing the principal lines of treatment for this pathology, only a minority of patients can be resected owing to cirrhosis or late diagnosis. Keeping in mind the end goal of conquering these challenges, new alternative approaches have been proposed. Accumulating evidence has demonstrated that epigallocatechin-3-gallate (EGCG), the principal catechin of green tea with multiple biological properties, is able to modulate different molecular mechanisms underlying HCC, mainly through its antioxidant activity. In this article, we revise these findings reported in the literature, in order to highlight the potential roles of EGCG in the treatment of HCC. The CAMARADES criteria were applied for quality assessment of animal studies, and a narrative synthesis performed. New bits of information available for translational perspectives into clinical practice are addressed.

Original languageEnglish
Pages (from-to)611-621
Number of pages11
JournalDrug Design, Development and Therapy
Volume13
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • epigallocatechin-3-gallate
  • hepatocellular carcinoma
  • preclinical studies
  • tumor progression

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives'. Together they form a unique fingerprint.

Cite this